Rion Aesthetics Initiates Series A

With the initiation of Series A funding, Rion Aesthetics presents a unique investment opportunity for aesthetic providers. Rion plans on closing the Series A in the second quarter of 2022.

Rion, a  regenerative aesthetic company pioneering the use of platelet-derived exosomes in both skincare as well as clinical applications in hair restoration and facial wrinkles, plans to use proceeds from the Series A to begin commercializing ( plated )™ SkinScience in US physician offices and complete proof of concept studies necessary to support FDA filings in the areas of hair restoration and facial wrinkles. 

“Aesthetic providers are at the forefront when it comes to launching innovative new treatments. We felt it was important to include them as we introduce platelet-derived exosomes, a new discovery in regenerative aesthetics,” says Alisa Lask, CEO, Rion Aesthetics.

“Our proprietary technology has already been recognized as a breakthrough innovation by leading aesthetic and investment organizations, including a recent award at the Aesthetics Innovation Summit (AIS) in April 2022.”

Clinical results, which the company expects to be published shortly, demonstrate the scientific depth behind the 15 years of science that went into the discovery of Renewosomes™, platelet-derived exosomes.

EDITOR'S NOTE: You can get updates from AIS, including an interview with Alisa Lask, at ModernAesthetics.tv.